An interventional study of Etta Vita GLP-1 Supplement Intervention in Overweight, Obesity and Appetite Dysregulation, sponsored by Etta Vita. Completed at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Etta Vita · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the effects of the Etta Vita GLP-1 supplement on appetite, gut health, and blood sugar over a 12-week period. Thirty participants with a BMI of 25 or greater and experiencing at least two of the following issues - food cravings, poor appetite control, irregular bowel movements, bloating, or gut issues - will use the test product daily.
The trial is a single-arm, open-label study in which all participants take two capsules of the supplement each morning, no more than 15 minutes before their first meal. Participants complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and attend their local clinic for blood tests (HbA1c, Glucose, and Leptin) at Baseline and Week 12.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's enrollment of 30 is below the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →This is the only study on the registry with Etta Vita as lead sponsor.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Etta Vita GLP-1 Supplement Intervention
All 30 participants receive the Etta Vita GLP-1 supplement (two capsules taken orally each morning, no more than 15 minutes before the first meal of the day) for 12 weeks.
Change in Blood Glucose via blood test
Mean change in fasting glucose (lab code 001032) from baseline to Week 12, assessed via blood test
Time frame: Baseline to Week 12
Change in HbA1c via blood test
Mean change in glycated hemoglobin (HbA1c, lab code 001453) from baseline to Week 12, assessed via blood test
Time frame: Baseline to Week 12
Change in Leptin via blood test
Mean change in serum leptin level (lab code 146712) from baseline to Week 12, assessed via blood test
Time frame: Baseline to Week 12
Change in Appetite via self-reported questionnaire
Mean change in self-reported appetite from baseline, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Food Cravings via self-reported questionnaire
Mean change in self-reported food cravings from baseline, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Bowel Movements via self-reported questionnaire
Mean change in self-reported bowel movement regularity from baseline, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Bloating via self-reported questionnaire
Mean change in self-reported bloating from baseline, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Gut Health via self-reported questionnaire
Mean change in self-reported gut issues from baseline, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Participant Perception of Product Effects on Blood Sugar via self-reported questionnaire
Self-reported perception of the supplement's effects on blood sugar, assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Ran from Apr 2026 to primary completion in Aug 2026, 4 months.
Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 4 months is below that.
Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.